Kalender

 

Dr. Noura Abul-Husn, clinical director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai, will provide insights on how PRS can be used to increase precision in risk assessment compared to current clinical genetic screening approaches, describe diverse patients’ perspectives on the use of clinical PRS, and discuss ongoing efforts to implement clinical PRS for common diseases in diverse populations. Professor Pradeep Natarajan, director of preventive cardiology at Massachusetts General Hospital, will discuss the limitations of contemporary guidelines in identifying patients at high risk of coronary artery disease and how PRS can help address this problem. Dr. George Busby, CSO & co-founder at Allelica, will discuss software available to enable PRS analysis implementation in-house at genetics laboratories and health systems and the best practices for clinical application.

Attendees will learn about:

• The role of PRS in estimating risk for cardiovascular and other common diseases.
• How PRS has been used to identify and rectify limitations in current risk assessments.
• How PRS is currently being integrated into patient care at leading healthcare institutions.

Website der Veranstaltung: https://event.on24.com/wcc/r/3465974/B23A386814408181A61CC3BAC175181F?partnerref=eblast2